Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
- PMID: 19092168
- PMCID: PMC2606812
- DOI: 10.2337/dc08-9026
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Erratum in
- Diabetes Care. 2009 Apr;32(4):754
Comment in
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al.Diabetes Care. 2009 Jul;32(7):e90-1; author reply e92-3. doi: 10.2337/dc09-9030. Diabetes Care. 2009. PMID: 19564469 No abstract available.
Similar articles
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.Circulation. 2009 Jan 20;119(2):351-7. doi: 10.1161/CIRCULATIONAHA.108.191305. Epub 2008 Dec 17. Circulation. 2009. PMID: 19095622 No abstract available.
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.J Am Coll Cardiol. 2009 Jan 20;53(3):298-304. doi: 10.1016/j.jacc.2008.10.008. J Am Coll Cardiol. 2009. PMID: 19147051 Review. No abstract available.
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al.Diabetes Care. 2009 Jul;32(7):e90-1; author reply e92-3. doi: 10.2337/dc09-9030. Diabetes Care. 2009. PMID: 19564469 No abstract available.
-
[Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].Rev Med Suisse. 2008 Aug 6;4(166):1734. Rev Med Suisse. 2008. PMID: 18777740 French. No abstract available.
-
The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.Can J Diabetes. 2015 Dec;39 Suppl 5:S155-9. doi: 10.1016/j.jcjd.2015.09.009. Can J Diabetes. 2015. PMID: 26654859 Review.
Cited by
-
A Case Study of the Impact of Data-Adaptive Versus Model-Based Estimation of the Propensity Scores on Causal Inferences from Three Inverse Probability Weighting Estimators.Int J Biostat. 2016 May 1;12(1):131-55. doi: 10.1515/ijb-2015-0028. Int J Biostat. 2016. PMID: 27227720 Free PMC article.
-
Longitudinal Adherence to Diabetes Quality Indicators and Cardiac Disease: A Nationwide Population-Based Historical Cohort Study of Patients With Pharmacologically Treated Diabetes.J Am Heart Assoc. 2022 Oct 4;11(19):e025603. doi: 10.1161/JAHA.122.025603. Epub 2022 Sep 21. J Am Heart Assoc. 2022. PMID: 36129044 Free PMC article.
-
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus.Cureus. 2021 Jan 31;13(1):e13045. doi: 10.7759/cureus.13045. Cureus. 2021. PMID: 33680590 Free PMC article.
-
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.Rev Endocr Metab Disord. 2016 Mar;17(1):117-27. doi: 10.1007/s11154-016-9351-6. Rev Endocr Metab Disord. 2016. PMID: 27106831 Review.
-
The glucose triad and its role in comprehensive glycaemic control: current status, future management.Int J Clin Pract. 2010 Nov;64(12):1705-11. doi: 10.1111/j.1742-1241.2010.02517.x. Epub 2010 Sep 23. Int J Clin Pract. 2010. PMID: 20860758 Free PMC article. Review.
References
-
- Reichard P, Bengt-Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304–309, 1993 - PubMed
-
- Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993 - PubMed
-
- Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117, 1995 - PubMed
-
- UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865, 1998 - PubMed
-
- UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical